2844 Results for "

Competitive inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (2844)

2844 Results for "Competitive inhibitor" in MCE Product Catalog:

Cat. No.: HY-170524
CAS No.: 3052313-73-9
Research Areas:  

Infection

TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
loading...
    loading...
Cat. No.: HY-148062
CAS No.: 2769753-48-0
Purity:  99.85%
RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC. RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].
loading...
    loading...
Cat. No.: HY-179427
NSD2/H3K36me2 modulator-1 is an orally active NSD2/H3K36me2 modulator. NSD2/H3K36me2 modulator-1 competitively binds to the SAM pocket of NSD2, potently inhibits NSD2 expression and suppresses H3K36me2 methylation. NSD2/H3K36me2 modulator-1 reverses epithelial-mesenchymal transition (EMT), inhibits cell migration, and induces G0/G1 phase arrest and apoptosis. NSD2/H3K36me2 modulator-1 induces decreased Mitochondrial membrane potential (MMP) and subsequent Reactive oxygen species (ROS) generation. NSD2/H3K36me2 modulator-1 can be used to research the NSD2-targeting epigenetic anticancer strategies for hepatocellular carcinoma (HCC) .
loading...
    loading...
Cat. No.: HY-179013
CAS No.: 812683-94-6
Research Areas:  

Infection

NS2B/NS3-IN-9 (Compound 73) is a broad-spectrum, non-competitive anti-Orthoflavivirus lipopeptide inhibitor targeting the NS2B-NS3 protease. NS2B/NS3-IN-9 exhibits IC50 values for Dengue virus DENV2 NS2B-NS3, West Nile virus WNV NS2B-NS3, and Zika virus ZIKV NS2B-NS3 of 2.4, 7.2, and 1.9 μM, respectively. NS2B/NS3-IN-9 also exhibits antiviral activity at the cellular level against DENV2, WNV, and ZIKV, with EC50 values of 4.1, 4.9, and 5.0 μM, respectively. NS2B/NS3-IN-9 has no significant toxicity to cells. NS2B/NS3-IN-9 can be used for the study of anti-Orthoflavivirus .
loading...
    loading...